Advisory Council on Alzheimer's Research, Care, and Services; Meeting, 72377-72378 [2019-28268]
Download as PDF
khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 84, No. 250 / Tuesday, December 31, 2019 / Notices
into Schedule I of the CSA. As such,
additional permanent controls will not
be necessary to fulfill United States
obligations if 5F–AMB is controlled
under Schedule II of the 1971
Convention.
5F-MDMB-PICA (5F-MDMB-2201)
(chemical name: methyl 2-(1-(5fluoropentyl)-1H-indazole-3carboxamido)-3,3-dimethylbutanoate) is
a synthetic cannabinoid that has been
sold online and used to mimic the
biological effects of THC, the main
psychoactive chemical constituent in
cannabis. Research and clinical reports
have demonstrated that synthetic
cannabinoids are applied onto plant
material so that the material may be
smoked as users attempt to obtain a
euphoric and psychoactive ‘‘high.’’
Synthetic cannabinoids have been
marketed under the guise of ‘‘herbal
incense,’’ and promoted by drug
traffickers as legal alternatives to
cannabis. 5F-MDMB-PICA has been
associated with law enforcement
seizures and overdoses requiring
emergency medical intervention. On
April 16, 2019, 5F-MDMB-PICA was
temporarily controlled as a Schedule I
substance under the CSA. As such,
additional permanent controls will be
necessary to fulfill United States
obligations if 5F-MDMB-PICA is
controlled under Schedule II of the 1971
Convention.
4F-MDMB-BINACA (4F-ADB)
(chemical name: methyl 2-(1-(4fluorobutyl)-1H-indazole-3carboxamido)-3,3-dimethylbutanoate) is
a synthetic cannabinoid that is a potent
full agonist at CB1 receptors. This
substance functionally (biologically)
mimics the effects of THC, a Schedule
I substance, and the main psychoactive
constituent in cannabis. 4F-MDMBBINACA has been encountered in
numerous synthetic cannabinoid
products that are smoked for their
psychoactive effects. Multiple law
enforcement encounters of 4F-MDMBBINACA have been reported involving
overdose deaths, illicit use, and seizures
of drug evidence between December
2018 and February 2019. There are no
commercial or approved medical uses
for 4F-MDMB-BINACA. 4F-MDMBBINACA is a positional isomer of 5FAMB (chemical name: methyl 2-(1-(5fluoropentyl)-1H-indazole-3carboxamido)-3-methylbutanoate), as
defined by 21 CFR 1300.01, and has
been a Schedule I controlled substance
under the CSA since April 10, 2017. As
such, additional permanent controls
will not be necessary to fulfill United
States obligations if 4F-MDMB-BINACA
is controlled under Schedule II of the
1971 Convention.
VerDate Sep<11>2014
17:30 Dec 30, 2019
Jkt 250001
4-CMC (4-chloromethcathinone;
clefedrone, clephedrone) (chemical
name: 1-(4-chlorophenyl)-2(methylamino)propan-1-one) is a
synthetic cathinone. 4-CMC produces
central nervous system stimulant effects
and is abused for its psychoactive
properties. 4-CMC abuse has been
associated with adverse health effects.
4-CMC has no currently accepted
medical use in treatment in the United
States. 4-CMC is not controlled under
the CSA, but it is considered a Schedule
I controlled substance by a number of
states in the United States. As such,
additional permanent controls will be
necessary to fulfill United States
obligations if 4-CMC is controlled under
Schedule II of the 1971 Convention.
N-Ethylhexedrone (chemical name: 2(ethylamino)-1-phenylhexan-1-one;
NEH, hexen, Ethyl-Hex) and alpha-PHP
(chemical name: 1-phenyl-2-(pyrrolidin1-yl)hexan-1-one; PV-7, apyrrolidinohexanophenone) are
synthetic cathinones. N-Ethylhexedrone
and alpha-PHP produce central nervous
system stimulant effects and are abused
for their psychoactive properties. NEthylhexedrone and alpha-PHP have
been associated with adverse health
effects leading to emergency department
admissions, and deaths. NEthylhexedrone and alpha-PHP have no
currently accepted medical use in
treatment in the United States. On July
18, 2019, N-Ethylhexedrone and alphaPHP were temporarily controlled as a
Schedule I substance under the CSA. As
such, additional permanent controls
will be necessary to fulfill United States
obligations if N-Ethylhexedrone and
alpha-PHP are controlled under
Schedule II of the 1971 Convention.
Flualprazolam and etizolam belong to
a class of substances known as
benzodiazepines. Benzodiazepines
produce central nervous system
depression and are commonly used to
treat insomnia, anxiety, and seizure
disorders. Etizolam is currently
prescribed in some countries; however,
neither drug substance is approved for
medical use in the United States.
Currently, flualprazolam and etizolam
are not controlled under the CSA, but
are controlled in a number of states in
the United States. As such, additional
permanent controls will be necessary to
fulfill United States obligations if
flualprazolam and etizolam are
controlled under Schedule IV of the
1971 Convention.
FDA, on behalf of the Secretary of
HHS, invites interested persons to
submit comments on the notifications
from the United Nations concerning
these drug substances. FDA, in
cooperation with the National Institute
PO 00000
Frm 00086
Fmt 4703
Sfmt 4703
72377
on Drug Abuse, will consider the
comments on behalf of HHS in
evaluating the WHO scheduling
recommendations. Then, under section
201(d)(2)(B) of the CSA, HHS will
recommend to the Secretary of State
what position the United States should
take when voting on the
recommendations for control of
substances under the 1971 Convention
at the CND meeting in March 2020.
Comments regarding the WHO
recommendations for control of crotonyl
fentanyl and valeryl fentanyl; under the
1961 Single Convention will also be
forwarded to the relevant Agencies for
consideration in developing the United
States position regarding narcotic
substances at the CND meeting.
Dated: December 23, 2019.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2019–28269 Filed 12–30–19; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Advisory Council on Alzheimer’s
Research, Care, and Services; Meeting
Assistant Secretary for
Planning and Evaluation, HHS.
ACTION: Notice of meeting.
AGENCY:
This notice announces the
public meeting of the Advisory Council
on Alzheimer’s Research, Care, and
Services (Advisory Council). The
Advisory Council provides advice on
how to prevent or reduce the burden of
Alzheimer’s disease and related
dementias on people with the disease
and their caregivers. During the January
27, 2020 meeting, an invited panel will
present lessons from epidemiology on
understanding current rates of
dementia, future trends, and potential
preventive strategies. The Advisory
Council will hear about the Department
of Defense’s Peer Reviewed Alzheimer’s
Research Program as well as an update
on the recommendations from the
Alzheimer’s Disease-Related Dementias
Research Summit. Federal workgroups
will also provide updates on work
completed in the last quarter.
DATES: The meeting will be held on
January 27, 2020 from 9:30 a.m. to 4:15
p.m. EST.
ADDRESSES: The meeting will be held in
Room 800 in the Hubert H. Humphrey
Building, 200 Independence Avenue
SW, Washington, DC 20201.
Comments: Time is allocated on the
agenda to hear public comments. The
time for oral comments will be limited
SUMMARY:
E:\FR\FM\31DEN1.SGM
31DEN1
72378
Federal Register / Vol. 84, No. 250 / Tuesday, December 31, 2019 / Notices
to three (3) minutes per individual. In
lieu of oral comments, formal written
comments may be submitted for the
record to Helen Lamont, Ph.D., OASPE,
200 Independence Avenue SW, Room
424E, Washington, DC 20201.
Comments may also be sent to napa@
hhs.gov. Those submitting written
comments should identify themselves
and any relevant organizational
affiliations.
FOR FURTHER INFORMATION CONTACT:
khammond on DSKJM1Z7X2PROD with NOTICES
Helen Lamont, 202–260–6075,
helen.lamont@hhs.gov. Note: Seating
may be limited. Those wishing to attend
the meeting must send an email to
napa@hhs.gov and put ‘‘January 27
Meeting Attendance’’ in the subject line
by Friday, January 17 so that their
names may be put on a list of expected
attendees and forwarded to the security
officers at the Department of Health and
Human Services. Any interested
member of the public who is a non-U.S.
citizen should include this information
at the time of registration to ensure that
the appropriate security procedure to
gain entry to the building is carried out.
Although the meeting is open to the
public, procedures governing security
and the entrance to Federal buildings
may change without notice. If you wish
to make a public comment, you must
note that within your email.
SUPPLEMENTARY INFORMATION: Notice of
these meetings is given under the
Federal Advisory Committee Act (5
U.S.C. App. 2, section 10(a)(1) and
(a)(2)). Topics of the Meeting: During
the January 27, 2020 meeting, an invited
panel will present lessons from
epidemiology on understanding current
rates of dementia, future trends, and
potential preventive strategies. The
Advisory Council will hear about the
Department of Defense’s Peer Reviewed
Alzheimer’s Research Program as well
as an update on the recommendations
from the Alzheimer’s Disease Related
Dementias Research Summit.
Procedure and Agenda: This meeting
is open to the public. Please allow 30
minutes to go through security and walk
to the meeting room. The meeting will
also be webcast at www.hhs.gov/live.
Authority: 42 U.S.C. 11225; Section 2(e)(3)
of the National Alzheimer’s Project Act. The
panel is governed by provisions of Public
Law 92–463, as amended (5 U.S.C. Appendix
2), which sets forth standards for the
formation and use of advisory committees.
Dated: December 19, 2019.
Brenda Destro,
Deputy Assistant Secretary for Planning and
Evaluation, Office of Human Services Policy.
[FR Doc. 2019–28268 Filed 12–30–19; 8:45 am]
BILLING CODE 4150–05–P
VerDate Sep<11>2014
17:30 Dec 30, 2019
Jkt 250001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Dental &
Craniofacial Research; Notice of
Meeting
Disorders Research, National Institutes of
Health, HHS)
Dated: December 23, 2019.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2019–28244 Filed 12–30–19; 8:45 am]
BILLING CODE 4140–01–P
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the National Advisory Dental
and Craniofacial Research Council.
The meeting will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Advisory
Dental and Craniofacial Research Council.
Date: January 29, 2020.
Open: 8:30 a.m. to 12:00 p.m.
Agenda: Report to the Director, NIDCR.
Place: National Institutes of Health,
Building 45, Conference Room E1/E2, 8600
Rockville Pike, Bethesda, MD 20892.
Closed: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 45, Conference Room E1/E2, 8600
Rockville Pike, Bethesda, MD 20892.
Contact Person: Alicia J. Dombroski, Ph.D.,
Director, Division of Extramural Activities,
National Institute of Dental and Craniofacial
Research, National Institutes of Health,
Bethesda, MD 20892, 301–594–4805,
adombroski@nidcr.nih.gov.
In the interest of security, NIH has
instituted stringent procedures for entrance
onto the NIH campus. All visitor vehicles,
including taxicabs, hotel, and airport shuttles
will be inspected before being allowed on
campus. Visitors will be asked to show one
form of identification (for example, a
government-issued photo ID, driver’s license,
or passport) and to state the purpose of their
visit.
Information is also available on the
Institute’s/Center’s home page: https://
www.nidcr.nih.gov/about, where an agenda
and any additional information for the
meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.121, Oral Diseases and
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Topics in Reproductive Biology.
Date: January 13, 2020.
Time: 1:00 p.m. to 2:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Telephone Conference
Call).
Contact Person: Hui Chen, MD, Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 6164, Bethesda, MD 20892, 301–
435–1044, chenhui@csr.nih.gov.
Name of Committee: Risk, Prevention and
Health Behavior Integrated Review Group;
Psychosocial Risk and Disease Prevention
Study Section.
Date: January 27–28, 2020.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Westgate Hotel, 1055 Second
Avenue, San Diego, CA 92101.
Contact Person: Stacey FitzSimmons,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3114,
MSC 7808, Bethesda, MD 20892, (301) 451–
9956, fitzsimmonss@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Psychosocial Risk and Disease Prevention
(PRDP).
Date: January 27, 2020.
E:\FR\FM\31DEN1.SGM
31DEN1
Agencies
[Federal Register Volume 84, Number 250 (Tuesday, December 31, 2019)]
[Notices]
[Pages 72377-72378]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-28268]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Advisory Council on Alzheimer's Research, Care, and Services;
Meeting
AGENCY: Assistant Secretary for Planning and Evaluation, HHS.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: This notice announces the public meeting of the Advisory
Council on Alzheimer's Research, Care, and Services (Advisory Council).
The Advisory Council provides advice on how to prevent or reduce the
burden of Alzheimer's disease and related dementias on people with the
disease and their caregivers. During the January 27, 2020 meeting, an
invited panel will present lessons from epidemiology on understanding
current rates of dementia, future trends, and potential preventive
strategies. The Advisory Council will hear about the Department of
Defense's Peer Reviewed Alzheimer's Research Program as well as an
update on the recommendations from the Alzheimer's Disease-Related
Dementias Research Summit. Federal workgroups will also provide updates
on work completed in the last quarter.
DATES: The meeting will be held on January 27, 2020 from 9:30 a.m. to
4:15 p.m. EST.
ADDRESSES: The meeting will be held in Room 800 in the Hubert H.
Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201.
Comments: Time is allocated on the agenda to hear public comments.
The time for oral comments will be limited
[[Page 72378]]
to three (3) minutes per individual. In lieu of oral comments, formal
written comments may be submitted for the record to Helen Lamont,
Ph.D., OASPE, 200 Independence Avenue SW, Room 424E, Washington, DC
20201. Comments may also be sent to [email protected]. Those submitting
written comments should identify themselves and any relevant
organizational affiliations.
FOR FURTHER INFORMATION CONTACT: Helen Lamont, 202-260-6075,
[email protected]. Note: Seating may be limited. Those wishing to
attend the meeting must send an email to [email protected] and put ``January
27 Meeting Attendance'' in the subject line by Friday, January 17 so
that their names may be put on a list of expected attendees and
forwarded to the security officers at the Department of Health and
Human Services. Any interested member of the public who is a non-U.S.
citizen should include this information at the time of registration to
ensure that the appropriate security procedure to gain entry to the
building is carried out. Although the meeting is open to the public,
procedures governing security and the entrance to Federal buildings may
change without notice. If you wish to make a public comment, you must
note that within your email.
SUPPLEMENTARY INFORMATION: Notice of these meetings is given under the
Federal Advisory Committee Act (5 U.S.C. App. 2, section 10(a)(1) and
(a)(2)). Topics of the Meeting: During the January 27, 2020 meeting, an
invited panel will present lessons from epidemiology on understanding
current rates of dementia, future trends, and potential preventive
strategies. The Advisory Council will hear about the Department of
Defense's Peer Reviewed Alzheimer's Research Program as well as an
update on the recommendations from the Alzheimer's Disease Related
Dementias Research Summit.
Procedure and Agenda: This meeting is open to the public. Please
allow 30 minutes to go through security and walk to the meeting room.
The meeting will also be webcast at www.hhs.gov/live.
Authority: 42 U.S.C. 11225; Section 2(e)(3) of the National
Alzheimer's Project Act. The panel is governed by provisions of
Public Law 92-463, as amended (5 U.S.C. Appendix 2), which sets
forth standards for the formation and use of advisory committees.
Dated: December 19, 2019.
Brenda Destro,
Deputy Assistant Secretary for Planning and Evaluation, Office of Human
Services Policy.
[FR Doc. 2019-28268 Filed 12-30-19; 8:45 am]
BILLING CODE 4150-05-P